Edwards Lifesciences initiated with an Outperform, $107 target at Baird

As previously reported, Baird analyst David Rescott initiated coverage of Edwards Lifesciences with an Outperform rating and $107 price target. Edwards should remain a leader as the TAVR market expands and new indications in the TAVR business as well as emerging TMTT sales should translate to a durable double-digit revenue growth trajectory through the end of the decade, the analyst tells investors in a research note.